# OnCo record bexobrutideg (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bexobrutideg/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bexobrutideg" ;
  schema:name "Bexobrutideg"@en ;
  schema:description "Bexobrutideg is an experimental protein degrader from Nurix Therapeutics in phase 3 trials for chronic lymphocytic leukaemia, aimed at BTK (Bruton tyrosine kinase)."@en ;
  schema:url <https://onco.cc/drugs/bexobrutideg/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=Bexobrutideg>, <https://www.nurixtx.com/pipeline/> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "protein degrader" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:companies <https://onco.cc/companies/nurix/> ;
  onco:trials <https://onco.cc/trials/nct07516093/>, <https://onco.cc/trials/nct07520006/>, <https://onco.cc/trials/nct07221500/> .